In the News / January 26, 2023
NovaResp Technologies Inc. Closes $2.0M Seed Plus Round
It is estimated that 1 billion people are affected by OSA (Obstructive Sleep Apnea) with 80% undiagnosed. CPAP (Continuous Positive Airway Pressure) therapy is the current gold standard for treating OSA, but adherence to treatment is lower than 50% after the first 3 months of use. By improving adherence to CPAP therapy:
cMAP™ is a platform software that uses artificial intelligence and machine learning during PAP therapy to predict and prevent episodes of apnea before they occur. As a result, personalized therapy can be delivered via PAP machines at lower, more comfortable air pressure levels.
Learn more about CMAP™
Learn about the benefits increased adherence can have for your company.
Contact Us
OSA is a sleep-related breathing disorder, affecting millions of people worldwide. Obstructive Sleep apnea is characterized by pauses in breathing or periods of shallow breathing during sleep. OSA is caused by complete (apnea) or partial (hypopnea) obstruction of the upper airway.
OSA can cause daytime sleepiness and impaired alertness. It can also lead to cardiovascular and neurological issues if left untreated.
Learn about the benefits increased adherence can have for your company
Contact Us